Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become more important with potential upcoming therapeutic interventions. Because serum creatinine level is considered of limited use and measurement of effective renal blood flow (ERBF) and total renal volume are time consuming and expensive, there is a need for other biomarkers. We aimed to investigate which urinary markers have increased levels in patients with ADPKD; whether these urinary markers are associated with measured glomerular filtration rate (mGFR), ERBF, and total renal volume; and whether these associations are independent of albuminuria (urine albumin excretion [UAE]).Study Design: Diagnostic test study.Setting & Participants: 102...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Introduction: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) ma...
Introduction: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) ma...
The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) makes it importa...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Introduction: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) ma...
Introduction: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) ma...
The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) makes it importa...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...
Background: Markers currently used to predict the likelihood of rapid disease progression in patient...